Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.69 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | SHBG | P04278 | 1/20 | 0.69 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.62 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.62 |
| ▸ | GABRP | O00591 | 2/20 | 0.61 |
| ▸ | GABRD | O14764 | 2/20 | 0.61 |
| ▸ | G6PD | P11413 | 2/20 | 0.61 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.61 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.61 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.61 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.61 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18891600 | 1.00 | LMNA (0.69) | LMNAGPBAR1CYP3A4SHBGSERPINA6 | |
| SCHEMBL8074397 | 1.00 | LMNA (0.69) | LMNAGPBAR1CYP3A4SHBGSERPINA6 | |
| SCHEMBL598581 | 1.00 | LMNA (0.69) | LMNAGPBAR1CYP3A4SHBGSERPINA6 | |
| SCHEMBL7413090 | 1.00 | LMNA (0.69) | LMNAGPBAR1CYP3A4SHBGSERPINA6 | |
| SCHEMBL7418009 | 1.00 | LMNA (0.69) | LMNAGPBAR1CYP3A4SHBGSERPINA6 | |
| SCHEMBL14027906 | 1.00 | LMNA (0.69) | LMNAGPBAR1CYP3A4SHBGSERPINA6 | |
| SCHEMBL14149787 | 1.00 | LMNA (0.69) | LMNAGPBAR1CYP3A4SHBGSERPINA6 | |
| SCHEMBL3644724 | 1.00 | LMNA (0.69) | LMNAGPBAR1CYP3A4SHBGSERPINA6 | |
| SCHEMBL2227935 | 1.00 | LMNA (0.69) | LMNAGPBAR1CYP3A4SHBGSERPINA6 | |
| SCHEMBL6241057 | 1.00 | LMNA (0.69) | LMNAGPBAR1CYP3A4SHBGSERPINA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11026953-B2 | 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor | ASARINA PHARMA AB (SE) | 2021-06-08 | — | — | US | disclosed |
| US-11026954-B2 | 3-beta-hydroxy-5-alpha-pregnan-20-one for use in medical treatment | ASARINA PHARMA AB (SE) | 2021-06-08 | — | — | US | disclosed |
| US-20210161915-A1 | GABA-A ANTAGONISTS FOR TREATING SUBSTANCE WITHDRAWAL DISORDERS | ASARINA PHARMA APS (DK) | 2021-06-03 | — | — | US | disclosed |
| EP-3773599-A1 | GABA-A ANTAGONISTS FOR TREATING SUBSTANCE WITHDRAWAL DISORDERS | Asarina Pharma ApS (DK) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019193138-A1 | GABA-A ANTAGONISTS FOR TREATING SUBSTANCE WITHDRAWAL DISORDERS | ASARINA PHARMA APS (DK) | 2019-10-10 | — | — | WO | disclosed |
| WO-2018147792-A1 | 3-BETA-HYDROXY-5-ALPHA-PREGNAN-20-ONE FOR USE IN MEDICAL TREATMENT | ASARINA PHARMA AB (SE) | 2018-08-16 | — | — | WO | disclosed |
| WO-2018147791-A1 | 3-BETA-HYDROXY-5-ALPHA-PREGNAN-20-ONE FOR USE IN TREATMENT OF ESSENTIAL TREMOR | ASARINA PHARMA AB (SE) | 2018-08-16 | — | — | WO | disclosed |
| EP-2711371-B1 | The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of CNS disorders | ASARINA PHARMA AB (SE) | 2018-01-10 | — | — | EP | disclosed |
| EP-2792681-B1 | The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders | UMECRINE AB (SE) | 2016-10-19 | — | — | EP | disclosed |
| US-20160272670-A1 | STEROIDS HAVING INCREASED WATER SOLUBILITY AND RESISTANCE AGAINST METABOLISM AND METHODS FOR THEIR PRODUCTION | UMECRINE AB (SE) | 2016-09-22 | — | — | US | disclosed |
| US-20120142657-A1 | GABA-STEROID ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | UMECRINE AB (SE) | 2012-06-07 | — | — | US | disclosed |
| US-8114860-B2 | 3beta-hydroxy-5alpha/beta-pregnan - steroids antagonism against 3alpha-hydroxy-5alpha-pregnan-20-one; enhanced GABA mediated chloride flux but with low GABA antagonism, pregnanes with an acetate group in 3 or in 3, 20 and 21 position partially inhibit GABA's own effect on the GABA mediated chloride flux | UMECRINE AB (SE) | 2012-02-14 | — | — | US | disclosed |
| EP-2097437-A1 | THE USE OF PREGNANE AND ANDROSTANE STEROIDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CNS DISORDERS | Umecrine AB (SE) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008063128-A1 | THE USE OF PREGNANE AND ANDROSTANE STEROIDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CNS DISORDERS | UMECRINE AB (SE) | 2008-05-29 | — | — | WO | disclosed |
| US-20080119416-A1 | NEW STEROIDS HAVING INCREASED WATER SOLUBILITY AND RESISTANCE AGAINST METABOLISM, AND METHODS FOR THEIR PRODUCTION | UMECRINE AB (SE) | 2008-05-22 | — | — | US | disclosed |
| US-20080070876-A1 | Gaba-Steroid Antagonists And Their Use For The Treatment Of Cns Disorders | UMECRINE AB (SE) | 2008-03-20 | — | — | US | disclosed |
| EP-1812009-A1 | GABA-STEROID ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | Umecrine AB (SE) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006054938-A1 | GABA-STEROID ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | UMECRINE AB (SE) | 2006-05-26 | — | — | WO | disclosed |
| EP-1458399-A1 | PREGNANE STEROIDS FOR USE IN THE TREATMENT OF CNS DISORDERS | Umecrine AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003059357-A1 | PREGNANE STEROIDS FOR USE IN THE TREATMENT OF CNS DISORDERS | UMECRINE AB (SE) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272670-A1 | STEROIDS HAVING INCREASED WATER SOLUBILITY AND RESISTANCE AGAINST METABOLISM AND METHODS FOR THEIR PRODUCTION | CYP11B1, CYP11A1, CYP11B2 | LMNA 2612/4885GPBAR1 381/4885CYP3A4 123/4885 |
| US-20080119416-A1 | NEW STEROIDS HAVING INCREASED WATER SOLUBILITY AND RESISTANCE AGAINST METABOLISM, AND METHODS FOR THEIR PRODUCTION | CYP21A2, CYP11B1, CYP11A1 | LMNA 3230/4885GPBAR1 392/4885CYP3A4 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.